Affimed N.V. (AFMD) expects to report topline data from its REDIRECT study in the fourth quarter of 2022. REDIRECT is a phase II, registration-directed study of its lead drug candidate AFM13 as monotherapy in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma.
from RTT - Earnings https://ift.tt/jdo8GuZ
via IFTTT
No comments:
Post a Comment